Skip to main content
. Author manuscript; available in PMC: 2011 Jul 13.
Published in final edited form as: Obesity (Silver Spring). 2010 Feb 25;18(9):1762–1767. doi: 10.1038/oby.2010.21

Figure 3.

Figure 3

Three-year cumulative incidence for development of abnormal ALT by quartile of (a) change in weight, (b) change in fasting plasma glucose concentrations, (c) change in fasting insulin concentrations. Bars represent standard errors. Includes individuals with normal ALT at baseline (below 95% sex-specific National Health and Nutrition Examination Survey cutoffs of 46 U/l for men and 35 U/l for women), incidence rates for development of abnormal ALT were calculated by quartiles of change in weight, FPG, and fasting insulin concentrations at year 1 for both placebo and metformin groups. The log rank test was used to compare cumulative incidence over the quartiles.